Evidence map›Paper›PMID 36921600›Full record

ArticleCell reports. Medicine2023

Pre-existing Fc profiles shape the evolution of neutralizing antibody breadth following influenza vaccination.

Carolyn M Boudreau, John S Burke, Alexander L Roederer, Matthew J Gorman, Sophia Mundle, Daniel Lingwood, Simon Delagrave, Saranya Sridhar, Ted M Ross, Harry Kleanthous and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cell reports. Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Carolyn M BoudreauPhD Program in Virology, Division of Medical Sciences, Harvard University, Boston, MA 02115, USA; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
John S BurkeRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Alexander L RoedererPhD Program in Virology, Division of Medical Sciences, Harvard University, Boston, MA 02115, USA; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Matthew J GormanRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Sophia MundleDiscovery North America, Sanofi-Pasteur, Inc., Cambridge, MA 02139, USA.
Daniel LingwoodRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Simon DelagraveRing Therapeutics, Cambridge, MA 02139, USA.
Saranya SridharDiscovery North America, Sanofi-Pasteur, Inc., Cambridge, MA 02139, USA.
Ted M RossUniversity of Georgia, Athens, GA 30602, USA.
Harry KleanthousBill & Melinda Gates Foundation, Seattle, WA 98109, USA.
Galit AlterRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA. Electronic address: ragonsystemserology@mgh.harvard.edu.
Ragon Institute of MGH, MIT and Harvard · USSanofi (United States) · USGates Foundation · USHarvard University · USUniversity of Georgia · US

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ARTHUR Y KIM · 2004 to 2026
$94.4M
MOLECULAR BASIS OF VIRAL INFECTIVITYT32AI007245 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI Aaron Gregory Schmidt · 1985 to 2026
$11.3M
Demystifying the antiviral activity of the IgG3+ antibody responseR37AI080289 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI ALTER, GALIT · 2015 to 2022
$5.8M
SARS-CoV-2 Variant TestingR01AI146785 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LINGWOOD, DANIEL · 2020 to 2024
$3.3M
Innate-like BCR activity as a template for universal vaccination against influenza virusR01AI137057 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI CHACKERIAN, BRYCE C, LINGWOOD, DANIEL · 2018 to 2022
$2.6M
Triggering germline-encoded broadly neutralizing antibody responses against influenza virusR01AI153098 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI BATISTA, FACUNDO DAMIAN, LINGWOOD, DANIEL · 2020 to 2023
$2.1M
Systemic coordination of pro-inflammatory immune reactions through dendritic cell-restricted sIL6R biogenesisR01AI155447 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LINGWOOD, DANIEL · 2021 to 2025
$2.0M
NIAID NIH HHS P30 AI060354NIAID NIH HHS R01 AI137057NIAID NIH HHS R01 AI146785NIAID NIH HHS R01 AI153098NIAID NIH HHS R01 AI155447NIAID NIH HHS R37 AI080289NIAID NIH HHS T32 AI007245
6 · The paper itself

Abstract

Under the ever-present threat of a pandemic influenza strain, the evolution of a broadly reactive, neutralizing, functional, humoral immune response may hold the key to protection against both circulating and emerging influenza strains. We apply a systems approach to profile hemagglutinin- and neuraminidase-specific humoral signatures that track with the evolution of broad immunity in a cohort of vaccinated individuals and validate these findings in a second longitudinal cohort. Multivariate analysis reveals the presence of a unique pre-existing Fcγ-receptor-binding antibody profile in individuals that evolved broadly reactive hemagglutination inhibition activity (HAI), marked by the presence of elevated levels of pre-existing FCGR2B-binding antibodies. Moreover, vaccination with FCGR2B-binding antibody-opsonized influenza results in enhanced antibody titers and HAI activity in a murine model. Together, these data suggest that pre-existing FCGR2B binding antibodies are a key correlate of the evolution of broadly protective influenza-specific antibodies, providing insight for the design of next-generation influenza vaccines.

Indexed as

Influenza, HumanInfluenza VaccinesAnimalsAntibodies, NeutralizingAntibodies, ViralHemagglutinin Glycoproteins, Influenza VirusHumansMiceVaccinationAntibodies, NeutralizingAntibodies, ViralHemagglutinin Glycoproteins, Influenza VirusInfluenza VaccinesantibodyFCGR2BFc receptorhemagglutination inhibitioninfluenzavaccine

Identifiers

PMID36921600
PMCPMC10040413
OpenAlexW4324195751

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.